Valneva announces pdufa date extension for chikungunya virus vaccine candidate

Saint - herblain ( france), august 14 , 2 02 3 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announced that the u.s. food and drug administration (fda) has revised the prescription drug user fee act (pdufa) action date for the biologics license application (bla) for vla1553, valneva's chikungunya virus vaccine candidate, from the previously communicated end of august to the end of november.
VALN Ratings Summary
VALN Quant Ranking